PaxMedica, Inc.
Empowering Possibilities, Transforming Lives: PaxMedica's Journey in Neurodevelopmental Solutions
Tarrytown, United States
7 employees
Post Ipo Equity
Total: $30.68M
Biotechnology, Pharmaceutical
General Information
Get notified when PaxMedica, Inc. moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track PaxMedica, Inc.
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biotechnology
About PaxMedica, Inc.
Taxonomy: biopharmaceutical company, neurodevelopmental disorders, Autism Spectrum Disorder, clinical-stage, innovative therapies, scientific innovation, Tarrytown, New York, unmet medical needs, drug development, neurological conditions, clinical trials, patient-centric approach
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | •••••• | - | 20 Nov 2023 | |
| Post-IPO Debt | •••••• | 1 |
|
03 Feb 2023 |
| Post-IPO Equity | •••••• | 1 |
|
17 Nov 2022 |
PaxMedica, Inc. Alternatives & Competitors
Autism is our expertise. Changing lives is our passion.
-logo.jpg "CCSN: The Center for Children with Special Needs"){kind=logo}
Unique Needs, Unique Care
FAQ About PaxMedica, Inc.
Don't just browse. Track.
Signal Tracker monitors PaxMedica, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
